Skip to content

Contact +44 (0) 20 7060 7474 email us

Company (Biotech)

Top 10 Biotechnology Companies

SWOT Analysis, Competitive Benchmarking, Financial Analysis and R&D Pipeline

Publication Date February 2010
Publisher GBI Research
Product Type Report
Pages 181
ISBN Number not applicable
Product Code GBI00022

Price

£2,310.00
approximately: $3,498 | €2,578

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Top 10 Biotechnology Companies - SWOT Analysis, Competitive Benchmarking, Financial Analysis and R&D Pipeline", which provides an insight into the global biotechnology industry and analyzes the competitive positioning of the top 10 companies in the industry. This pharmaceutical and healthcare report estimates the market size of the global biotechnology industry and its future prospects. It benchmarks the leading companies in the biotechnology industry on selected parameters to analyze their competitive positioning in the market. The report analyzes the future landscape of the biotechnology industry by forecasting the revenues of leading companies to 2012. For each company the report analyzes the financial strength, product portfolio, pipeline strength and therapeutic focus of its R&D activities. It critically examines the strengths and weaknesses of individual companies and the opportunities and threats facing them.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Scope

The report analyses the competitive landscape of the biotechnology industry, R&D strategies and pipeline of the top 10 players, and strengths, weaknesses, opportunities and threats facing these companies. Its scope includes

  • Market size of the global biotechnology industry and coverage of the changing competitive landscape from 2008 to 2012.
  • Review of key industry drivers and restraints which are likely to impact the global biotechnology industry in the future.
  • Analysis of the competitive positioning of the top 10 biotechnology companies globally.
  • Analysis of pipeline products in the global biotech market by therapy area like cancer, infectious diseases, respiratory disorders, autoimmune disorders, and product classes.
  • Financial analysis including annual revenues of top 10 companies from 2004 to 2008, with forecasts to 2012.
  • SWOT analysis, DuPont analysis and financial benchmarking of the top 10 biotech companies.
  • Analysis of the therapeutic focus, marketed products and product pipeline of top 10 biotech companies.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

  • Develop a clear knowledge and understanding of the competitive landscape and how this will change in the coming years.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Effectively plan your M&A and partnership strategies by identifying companies with the most promising pipeline.
  • Make more informed business decisions from the insightful and in-depth analysis of the key strategies to be followed by competitors.
  • Effectively plan your investment strategies by identifying companies with maximum investment potential.
  • Identify key winners and losers and who is best positioned to take advantage of the emerging market opportunities.

Contents

  • 1 Table of Contents
  • 1 Table of Contents
    • 1.1 List of Tables
    • 1.2 List of Figures
  • 2 Introduction
    • 2.1 GBI Research Report Guidance
  • 3 Global Biotechnology Industry - Market Characterization
    • 3.1 Global Biotechnology Industry - Market Size
    • 3.2 Top 10 Companies - Market Forecast
    • 3.3 Therapeutic Focus of the Biotechnology Industry
    • 3.4 Global Biotechnology Industry - Growth Drivers and Restraints
      • 3.4.1 Growth Drivers
      • 3.4.2 Restraints
  • 4 Top 10 Biotechnology Companies - Competitive Landscape
    • 4.1 Competitive Landscape Framework
    • 4.2 Financial Benchmarking
      • 4.2.1 Earnings per Share
      • 4.2.2 Net Profit Margin
      • 4.2.3 Current Ratio
      • 4.2.4 Debt to Equity ratio
      • 4.2.5 Asset Turnover Ratio
    • 4.3 R&D Productivity Framework
  • 5 Global Biotechnology Industry - Strategic Consolidations
    • 5.1 Pharma Biotech Space - Deals Analysis (2008)
    • 5.2 Increasing Interest of Big Pharma Companies in the Biotech Industry
  • 6 Top 10 Biotechnology Companies - Amgen
    • 6.1 Company Overview
      • 6.1.1 Introduction
      • 6.1.2 Business Description
    • 6.2 Strategic Positioning
      • 6.2.1 SWOT Analysis
    • 6.3 Financial Analysis
      • 6.3.1 Revenue Analysis and Forecasts
      • 6.3.2 Ratio Analysis
      • 6.3.3 DuPont Analysis
    • 6.4 Marketed Products
      • 6.4.1 Key Marketed Products
    • 6.5 R&D Strategies
      • 6.5.1 Therapeutic Focus
      • 6.5.2 R&D Productivity
    • 6.6 Product Pipeline
      • 6.6.1 Overview
      • 6.6.2 Key Pipeline Products
    • 6.7 Licensing Agreements
      • 6.7.1 Overview
  • 7 Top 10 Biotechnology Companies - Genentech (Roche)
    • 7.1 Company Overview
      • 7.1.1 Introduction
      • 7.1.2 Business Description
    • 7.2 Strategic Positioning
      • 7.2.1 SWOT Analysis
    • 7.3 Financial Analysis
      • 7.3.1 Revenue Analysis and Forecasts
      • 7.3.2 Ratio Analysis
      • 7.3.3 DuPont Analysis
    • 7.4 Marketed Products
      • 7.4.1 Key Marketed Products
    • 7.5 R&D Strategies
      • 7.5.1 Therapeutic Focus
      • 7.5.2 R&D Productivity
    • 7.6 Product Pipeline
      • 7.6.1 Overview
      • 7.6.2 Key Pipeline Products
    • 7.7 Licensing Agreements
      • 7.7.1 Overview
  • 8 Top 10 Biotechnology Companies - Gilead Sciences
    • 8.1 Company Overview
      • 8.1.1 Introduction
      • 8.1.2 Business Description
    • 8.2 Strategic Positioning
      • 8.2.1 SWOT Analysis
    • 8.3 Financial Analysis
      • 8.3.1 Revenue Analysis and Forecasts
      • 8.3.2 Ratio Analysis
      • 8.3.3 DuPont Analysis
    • 8.4 Marketed Products
      • 8.4.1 Key Marketed Products
    • 8.5 R&D Strategies
      • 8.5.1 Therapeutic Focus
      • 8.5.2 R&D Productivity
    • 8.6 Product Pipeline
      • 8.6.1 Overview
      • 8.6.2 Key Pipeline Products
    • 8.7 Licensing Agreements
      • 8.7.1 Overview
  • 9 Top 10 Biotechnology Companies - UCB Pharma
    • 9.1 Company Overview
      • 9.1.1 Introduction
      • 9.1.2 Business Description
    • 9.2 Strategic Positioning
      • 9.2.1 SWOT Analysis
    • 9.3 Financial Analysis
      • 9.3.1 Revenue Analysis and Forecasts
      • 9.3.2 Ratio Analysis
      • 9.3.3 DuPont Analysis
    • 9.4 Marketed Products
      • 9.4.1 Key Marketed Products
    • 9.5 R&D Strategies
      • 9.5.1 Therapeutic Focus
      • 9.5.2 R&D Productivity
    • 9.6 Product Pipeline
      • 9.6.1 Overview
      • 9.6.2 Key Pipeline Products
    • 9.7 Licensing Agreements
      • 9.7.1 Overview
  • 10 Top 10 Biotechnology Companies - Genzyme
    • 10.1 Company Overview
      • 10.1.1 Introduction
      • 10.1.2 Business Description
    • 10.2 Strategic Positioning
      • 10.2.1 SWOT Analysis
    • 10.3 Financial Analysis
      • 10.3.1 Revenue Analysis and Forecasts
      • 10.3.2 Ratio Analysis
      • 10.3.3 DuPont Analysis
    • 10.4 Marketed Products
      • 10.4.1 Key Marketed Products
    • 10.5 R&D Strategies
      • 10.5.1 Therapeutic Focus
      • 10.5.2 R&D Productivity
    • 10.6 Product Pipeline
      • 10.6.1 Overview
      • 10.6.2 Key Pipeline Products
    • 10.7 Licensing Agreements
      • 10.7.1 Overview
  • 11 Top 10 Biotechnology Companies - Biogen Idec
    • 11.1 Company Overview
      • 11.1.1 Introduction
      • 11.1.2 Business Description
    • 11.2 Strategic Positioning
      • 11.2.1 SWOT Analysis
    • 11.3 Financial Analysis
      • 11.3.1 Revenue Analysis and Forecasts
      • 11.3.2 Ratio Analysis
      • 11.3.3 DuPont Analysis
    • 11.4 Marketed Products
      • 11.4.1 Key Marketed Products
    • 11.5 R&D Strategies
      • 11.5.1 Therapeutic Focus
      • 11.5.2 R&D Productivity
    • 11.6 Product Pipeline
      • 11.6.1 Overview
      • 11.6.2 Key Pipeline Products
    • 11.7 Licensing Agreements
      • 11.7.1 Overview
  • 12 Top 10 Biotechnology Companies - CSL Limited
    • 12.1 Company Overview
      • 12.1.1 Introduction
      • 12.1.2 Business Description
    • 12.2 Strategic Positioning
      • 12.2.1 SWOT Analysis
    • 12.3 Financial Analysis
      • 12.3.1 Revenue Analysis and Forecasts
      • 12.3.2 Ratio Analysis
      • 12.3.3 DuPont Analysis
    • 12.4 Marketed Products
      • 12.4.1 Key Marketed Products
    • 12.5 R&D Strategies
      • 12.5.1 Therapeutic Focus
      • 12.5.2 R&D Productivity
    • 12.6 Product Pipeline
      • 12.6.1 Overview
      • 12.6.2 Key Pipeline Products
    • 12.7 Licensing Agreements
      • 12.7.1 Overview
  • 13 Top 10 Biotechnology Companies - Celgene
    • 13.1 Company Overview
      • 13.1.1 Introduction
      • 13.1.2 Business Description
    • 13.2 Strategic Positioning
      • 13.2.1 SWOT Analysis
    • 13.3 Financial Analysis
      • 13.3.1 Revenue Analysis and Forecasts
      • 13.3.2 Ratio Analysis
      • 13.3.3 DuPont Analysis
    • 13.4 Marketed Products
      • 13.4.1 Key Marketed Products
    • 13.5 R&D Strategies
      • 13.5.1 Therapeutic Focus
      • 13.5.2 R&D Productivity
    • 13.6 Product Pipeline
      • 13.6.1 Overview
      • 13.6.2 Key Pipeline Products
    • 13.7 Licensing Agreements
      • 13.7.1 Overview
  • 14 Top 10 Biotechnology Companies - Cephalon
    • 14.1 Company Overview
      • 14.1.1 Introduction
      • 14.1.2 Business Description
    • 14.2 Strategic Positioning
      • 14.2.1 SWOT Analysis
    • 14.3 Financial Analysis
      • 14.3.1 Revenue Analysis and Forecasts
      • 14.3.2 Ratio Analysis
      • 14.3.3 DuPont Analysis
    • 14.4 Marketed Products
      • 14.4.1 Key Marketed Products
    • 14.5 R&D Strategies
      • 14.5.1 Therapeutic Focus
      • 14.5.2 R&D Productivity
    • 14.6 Product Pipeline
      • 14.6.1 Overview
      • 14.6.2 Key Pipeline Products
    • 14.7 Licensing Agreements
      • 14.7.1 Overview
  • 15 Top 10 Biotechnology Companies - Actelion
    • 15.1 Company Overview
      • 15.1.1 Introduction
      • 15.1.2 Business Description
    • 15.2 Strategic Positioning
      • 15.2.1 SWOT Analysis
    • 15.3 Financial Analysis
      • 15.3.1 Revenue Analysis and Forecasts
      • 15.3.2 Ratio Analysis
      • 15.3.3 DuPont Analysis
    • 15.4 Marketed Products
      • 15.4.1 Key Marketed Products
    • 15.5 R&D Strategies
      • 15.5.1 Therapeutic Focus
      • 15.5.2 R&D Productivity
    • 15.6 Product Pipeline
      • 15.6.1 Overview
      • 15.6.2 Key Pipeline Products
    • 15.7 Licensing Agreements
      • 15.7.1 Overview
  • 16 Top 10 Biotechnology Companies - Appendix
    • 16.1 Market Definitions
    • 16.2 Abbreviations
    • 16.3 Research Methodology
      • 16.3.1 Coverage
      • 16.3.2 Secondary Research
      • 16.3.3 Primary Research
      • 16.3.4 Expert Panel Validation
    • 16.4 Contact Us
    • 16.5 Disclaimer
    • 16.6 Sources
  • 1.1 List of Tables
    • Table 1: Top 10 Biotechnology Companies, Global, Annual Revenues, ($m), 2008
    • Table 2: Global, Top 25 Biologic Drugs by Annual Sales. 2008
    • Table 3: Top 10 Biotechnology Companies, Global, Revenue Forecast, ($m), 2008-2012
    • Table 4: Top 10 Biotechnology Companies, Global, Company Rankings, 2008-2012
    • Table 5: Top 10 Biotechnology Companies, Global, Rankings by Strength of Marketed and Pipeline Products, 2008
    • Table 6: Top 10 Biotechnology Companies, Global, Earnings per Share, ($), 2008
    • Table 7: Top 10 Biotechnology Companies, Global, Net Profit Margin, (%), 2008
    • Table 8: Top 10 Biotechnology Companies, Global, Current Ratio, 2008
    • Table 9: Top 10 Biotechnology Companies, Global, Debt to Equity Ratio, 2008
    • Table 10: Top 10 Biotechnology Companies, Global, Asset Turnover Ratio, 2008
    • Table 11: Top 10 Biotechnology Companies, Global, Rankings by Strength of Pipeline Products in Each Therapy Area (1), 2008
    • Table 12: Top 10 Biotechnology Companies, Global, Rankings by Strength of Pipeline Products in Each Therapy Area (2), 2008
    • Table 13: Biotechnology Industry, Global, Key M&A Deals in 2008
    • Table 14: Global, Value of Drugs Going Off-Patent by Therapeutic Area, ($m), 2009-2014
    • Table 15: Amgen Inc., Historical Revenue, ($m), 2004-2008
    • Table 16: Amgen Inc., Revenue Forecast, ($m), 2008-2012
    • Table 17: Amgen Inc., Net Income and R&D Expense, ($m), 2004-2008
    • Table 18: Equity Ratios for Amgen Inc., ($), 2004-2008
    • Table 19: Profitability Ratios for Amgen Inc., (%), 2004-2008
    • Table 20: Liquidity Ratios for Amgen Inc., 2004-2008
    • Table 21: Leverage Ratios for Amgen Inc., 2004-2008
    • Table 22: Efficiency Ratios for Amgen Inc., 2004-2008
    • Table 23: Expenditure on R&D for Amgen Inc., ($m), 2004-2008
    • Table 24: Phase-wise Analysis of Amgen R&D Pipeline, 2009
    • Table 25: Amgen Inc., Licensing Agreements for Drugs, 2008-July 2009
    • Table 26: Genentech, Historical Revenue, ($m), 2004-2008
    • Table 27: Genentech, Revenue Forecast, ($m), 2008-2012
    • Table 28: Genentech, Net Income and R&D Expense, ($m), 2004-2008
    • Table 29: Equity Ratios for Genentech, ($), 2004-2008
    • Table 30: Profitability Ratios for Genentech, (%), 2004-2008
    • Table 31: Liquidity Ratios for Genentech, 2004-2008
    • Table 32: Leverage Ratios for Genentech, 2004-2008
    • Table 33: Efficiency Ratios for Genentech, 2004-2008
    • Table 34: Expenditure on R&D for Genentech, ($m), 2004-2008
    • Table 35: Phase-wise Analysis of Genentech R&D Pipeline, 2009
    • Table 36: Genentech, Licensing Agreements for Drugs, 2008-July 2009
    • Table 37: Gilead, Historical Revenue, ($m), 2004-2008
    • Table 38: Gilead, Revenue Forecast, ($m), 2008-2012
    • Table 39: Gilead, Net Income and R&D Expense, ($m), 2004-2008
    • Table 40: Equity Ratios for Gilead, ($), 2004-2008
    • Table 41: Profitability Ratios for Gilead, (%), 2004-2008
    • Table 42: Liquidity Ratios for Gilead, 2004-2008
    • Table 43: Leverage Ratios for Gilead, 2004-2008
    • Table 44: Efficiency Ratios for Gilead, 2004-2008
    • Table 45: Expenditure on R&D by Gilead, ($m), 2004-2008
    • Table 46: Phase-wise Analysis of Gilead R&D Pipeline, 2009
    • Table 47: Gilead, Licensing Agreements for Drugs, 2008-July 2009
    • Table 48: UCB Pharma, Historical Revenue, ($m), 2004-2008
    • Table 49: UCB Pharma, Revenue Forecast, ($m), 2008-2012
    • Table 50: UCB Pharma, Net Income and R&D Expense, ($m), 2004-2008
    • Table 51: Equity Ratios for UCB Pharma, ($), 2004-2008
    • Table 52: Profitability Ratios for UCB Pharma, (%), 2004-2008
    • Table 53: Liquidity Ratios for UCB Pharma, 2004-2008
    • Table 54: Leverage Ratios for UCB Pharma, 2004-2008
    • Table 55: Efficiency Ratios for UCB Pharma, 2004-2008
    • Table 56: Expenditure on R&D by UCB Pharma, ($m), 2004-2008
    • Table 57: Phase-wise Analysis of UCB Pharma R&D Pipeline, 2009
    • Table 58: UCB Pharma, Licensing Agreements for Drugs, 2008-July 2009
    • Table 59: Genzyme, Historical Revenue, ($m), 2004-2008
    • Table 60: Genzyme, Revenue Forecast, ($m), 2008-2012
    • Table 61: Genzyme, Net Income and R&D Expense, ($m), 2004-2008
    • Table 62: Equity Ratios for Genzyme, ($), 2004-2008
    • Table 63: Profitability Ratios for Genzyme, (%), 2004-2008
    • Table 64: Liquidity Ratios for Genzyme, 2004-2008
    • Table 65: Leverage Ratios for Genzyme, 2004-2008
    • Table 66: Efficiency Ratios for Genzyme, 2004-2008
    • Table 67: Expenditure on R&D by Genzyme, ($m), 2004-2008
    • Table 68: Phase-wise Analysis of Genzyme R&D Pipeline, 2009
    • Table 69: Genzyme, Licensing Agreements for Drugs, 2008-July 2009
    • Table 70: Biogen Idec, Historical Revenue, ($m), 2004-2008
    • Table 71: Biogen Idec, Revenue Forecast, ($m), 2008-2012
    • Table 72: Biogen Idec, Net Income and R&D Expense, ($m), 2004-2008
    • Table 73: Equity Ratios for Biogen Idec, ($), 2004-2008
    • Table 74: Profitability Ratios for Biogen Idec, (%), 2004-2008
    • Table 75: Liquidity Ratios for Biogen Idec, 2004-2008
    • Table 76: Leverage Ratios for Biogen Idec, 2004-2008
    • Table 77: Efficiency Ratios for Biogen Idec, 2004-2008
    • Table 78: Expenditure on R&D for Biogen Idec, ($m), 2004-2008
    • Table 79: Phase-wise Analysis of Biogen Idec R&D Pipeline, 2009
    • Table 80: Biogen Idec, Licensing Agreements for Drugs, 2008-July 2009
    • Table 81: CSL Limited, Historical Revenue, ($m), 2005-2009
    • Table 82: CSL Limited, Revenue Forecast, ($m), 2009-2013
    • Table 83: CSL Limited, Net Income and R&D Expense, ($m), 2005-2009
    • Table 84: Equity Ratios for CSL Limited, ($), 2005-2009
    • Table 85: Profitability Ratios for CSL Limited, (%), 2005-2009
    • Table 86: Liquidity Ratios for CSL Limited, 2005-2009
    • Table 87: Leverage Ratios for CSL Limited, 2005-2009
    • Table 88: Efficiency Ratios for CSL Limited, 2005-2009
    • Table 89: Expenditure on R&D by CSL Limited, ($m), 2005-2009
    • Table 90: Phase-wise Analysis of CSL Limited R&D Pipeline, 2009
    • Table 91: CSL Limited, Licensing Agreements for Drugs, 2008-July 2009
    • Table 92: Celgene, Historical Revenue, ($m), 2004-2008
    • Table 93: Celgene, Revenue Forecast, ($m), 2008-2012
    • Table 94: Celgene, Net Income and R&D Expense, ($m), 2004-2008
    • Table 95: Equity Ratios for Celgene, ($), 2004-2008
    • Table 96: Profitability Ratios for Celgene, (%), 2004-2008
    • Table 97: Liquidity Ratios for Celgene, 2004-2008
    • Table 98: Leverage Ratios for Celgene, 2004-2008
    • Table 99: Efficiency Ratios for Celgene, 2004-2008
    • Table 100: Expenditure on R&D by Celgene, ($m), 2004-2008
    • Table 101: Phase-wise Analysis of Celgene R&D Pipeline, 2009
    • Table 102: Celgene, Licensing Agreements for Drugs, 2008-July 2009
    • Table 103: Cephalon, Historical Revenue, ($m), 2004-2008
    • Table 104: Cephalon, Revenue Forecast, ($m), 2008-2012
    • Table 105: Cephalon, Net Income and R&D Expense, ($m), 2004-2008
    • Table 106: Equity Ratios for Cephalon, ($), 2004-2008
    • Table 107: Profitability Ratios for Cephalon, (%), 2004-2008
    • Table 108: Liquidity Ratios for Cephalon, 2004-2008
    • Table 109: Leverage Ratios for Cephalon, 2004-2008
    • Table 110: Efficiency Ratios for Cephalon, 2004-2008
    • Table 111: Expenditure on R&D for Cephalon, ($m), 2004-2008
    • Table 112: Phase-wise Analysis of Cephalon R&D Pipeline, 2009
    • Table 113: Cephalon, Licensing Agreements for Drugs, 2008-July 2009
    • Table 114: Actelion, Historical Revenue, ($m), 2004-2008
    • Table 115: Actelion, Revenue Forecast, ($m), 2008-2012
    • Table 116: Actelion, Net Income and R&D Expense, ($m), 2004-2008
    • Table 117: Equity Ratios for Actelion, ($), 2004-2008
    • Table 118: Profitability Ratios for Actelion, (%), 2004-2008
    • Table 119: Liquidity Ratios for Actelion, 2004-2008
    • Table 120: Leverage Ratios for Actelion, 2004-2008
    • Table 121: Efficiency Ratios for Actelion, 2004-2008
    • Table 122: Expenditure on R&D by Actelion, ($m), 2004-2008
    • Table 123: Phase-wise Analysis of Actelion R&D Pipeline, 2009
    • Table 124: Actelion, Licensing Agreements for Drugs, 2008-July 2009
  • 1.2 List of Figures
    • Figure 1: Top 10 Biotechnology Companies, Global, Annual Revenues, ($m), 2008
    • Figure 2: Top 10 Biotechnology Companies, Global, Revenue Forecast, ($m), 2008-2012
    • Figure 3: Global, Biotech Pipeline Drugs by Therapy Areas, (%), 2008
    • Figure 4: Global, Biotech Pipeline Drugs by Product Classes, 2008
    • Figure 5: Biotechnology Industry, Global, Growth Drivers and Restraints,2008
    • Figure 6: Top 10 Biotechnology Companies, Global, Competitive Positioning, 2008
    • Figure 7: Top 10 Biotechnology Companies, Global, Competitive Landscape Framework, 2008
    • Figure 8: Top 10 Biotechnology Companies, Global, R&D Productivity Framework, 2008
    • Figure 9: Global, Value of Drugs Going Off-Patent by Therapeutic Area, ($m), 2009-2014
    • Figure 10: SWOT Analysis of Amgen Inc
    • Figure 11: Amgen Inc., Annual Revenue Forecasts, ($m), 2004-2012
    • Figure 12: Amgen Inc., Net Income and R&D Expense, ($m), 2004-2008
    • Figure 13: Amgen Inc., Earnings per Share, ($), 2004-2008
    • Figure 14: Amgen Inc., Net Profit Margin, (%), 2004-2008
    • Figure 15: Amgen Inc., Current Ratio, 2004-2008
    • Figure 16: Amgen Inc., Debt to Equity Ratio, 2004-2008
    • Figure 17: Amgen Inc., Return on Equity, (%), 2004-2008
    • Figure 18: DuPont Analysis for Amgen Inc., 2004-2008
    • Figure 19: Therapeutic Focus of Amgen R&D Pipeline, 2009
    • Figure 20: R&D Productivity for Amgen Inc., 2004-2008
    • Figure 21: Phase-wise Analysis of Amgen R&D Pipeline, 2009
    • Figure 22: SWOT Analysis of Genentech
    • Figure 23: Genentech, Annual Revenue Forecasts, ($m), 2004-2012
    • Figure 24: Genentech, Net Income and R&D Expense, ($m), 2004-2008
    • Figure 25: Genentech, Earnings per Share, ($), 2004-2008
    • Figure 26: Genentech, Net Profit Margin, (%), 2004-2008
    • Figure 27: Genentech, Current Ratio, 2004-2008
    • Figure 28: Genentech, Debt to Equity Ratio, 2004-2008
    • Figure 29: Genentech, Return on Equity, (%), 2004-2008
    • Figure 30: DuPont Analysis for Genentech, 2004-2008
    • Figure 31: Therapeutic Focus of Genentech R&D Pipeline, 2009
    • Figure 32: R&D Productivity for Genentech, 2004-2008
    • Figure 33: Phase-wise Analysis of Genentech R&D Pipeline, 2009
    • Figure 34: SWOT Analysis of Gilead
    • Figure 35: Gilead, Annual Revenue Forecasts, ($m), 2004-2012
    • Figure 36: Gilead, Net Income and R&D Expense, ($m), 2004-2008
    • Figure 37: Gilead, Earnings per Share, ($), 2004-2008
    • Figure 38: Gilead, Net Profit Margin, (%), 2004-2008
    • Figure 39: Gilead, Current Ratio, 2004-2008
    • Figure 40: Gilead, Debt to Equity Ratio, 2004-2008
    • Figure 41: Gilead, Return on Equity, (%), 2004-2008
    • Figure 42: DuPont Analysis for Gilead, 2004-2008
    • Figure 43: Therapeutic Focus of Gilead R&D Pipeline, 2009
    • Figure 44: R&D Productivity for Gilead, 2004-2008
    • Figure 45: Phase-wise Analysis of Gilead R&D Pipeline, 2009
    • Figure 46: SWOT Analysis of UCB Pharma
    • Figure 47: UCB Pharma, Annual Revenue Forecasts, ($m), 2004-2012
    • Figure 48: UCB Pharma, Net Income and R&D Expense, ($m), 2004-2008
    • Figure 49: UCB Pharma, Earnings per Share, ($), 2004-2008
    • Figure 50: UCB Pharma, Net Profit Margin, (%), 2004-2008
    • Figure 51: UCB Pharma, Current Ratio, 2004-2008
    • Figure 52: UCB Pharma, Debt to Equity Ratio, 2004-2008
    • Figure 53: UCB Pharma, Return on Equity, (%), 2004-2008
    • Figure 54: DuPont Analysis for UCB Pharma, 2004-2008
    • Figure 55: Therapeutic Focus of UCB Pharma R&D Pipeline, 2009
    • Figure 56: R&D Productivity for UCB Pharma, 2004-2008
    • Figure 57: Phase-wise Analysis of UCB Pharma R&D Pipeline, 2009
    • Figure 58: SWOT Analysis of Genzyme
    • Figure 59: Genzyme, Annual Revenue Forecasts, ($m), 2004-2012
    • Figure 60: Genzyme, Net Income and R&D Expense, ($m), 2004-2008
    • Figure 61: Genzyme, Earnings per Share, ($), 2004-2008
    • Figure 62: Genzyme, Net Profit Margin, (%), 2004-2008
    • Figure 63: Genzyme, Current Ratio, 2004-2008
    • Figure 64: Genzyme, Debt to Equity Ratio, 2004-2008
    • Figure 65: Genzyme, Return on Equity, (%), 2004-2008
    • Figure 66: DuPont Analysis for Genzyme, 2004-2008
    • Figure 67: Therapeutic Focus of Genzyme R&D Pipeline, 2009
    • Figure 68: R&D Productivity for Genzyme, 2004-2008
    • Figure 69: Phase-wise Analysis of Genzyme R&D Pipeline, 2009
    • Figure 70: SWOT Analysis of Biogen Idec
    • Figure 71: Biogen Idec, Annual Revenue Forecasts, ($m), 2004-2012
    • Figure 72: Biogen Idec, Net Income and R&D Expense, ($m), 2004-2008
    • Figure 73: Biogen Idec, Earnings per Share, ($), 2004-2008
    • Figure 74: Biogen Idec, Net Profit Margin, (%), 2004-2008
    • Figure 75: Biogen Idec, Current Ratio, 2004-2008
    • Figure 76: Biogen Idec, Debt to Equity Ratio, 2004-2008
    • Figure 77: Biogen Idec, Return on Equity, (%), 2004-2008
    • Figure 78: DuPont Analysis for Biogen Idec, 2004-2008
    • Figure 79: Therapeutic Focus of Biogen Idec R&D Pipeline, 2009
    • Figure 80: R&D Productivity for Biogen Idec, 2004-2008
    • Figure 81: Phase-wise Analysis of Biogen Idec R&D Pipeline, 2009
    • Figure 82: SWOT Analysis of CSL Limited
    • Figure 83: CSL Limited, Annual Revenue Forecasts, ($m), 2005-2013
    • Figure 84: CSL Limited, Net Income and R&D Expense, ($m), 2005-2009
    • Figure 85: CSL Limited, Earnings per Share, ($), 2005-2009
    • Figure 86: CSL Limited, Net Profit Margin, (%), 2005-2009
    • Figure 87: CSL Limited, Current Ratio, 2005-2009
    • Figure 88: CSL Limited, Debt to Equity Ratio, 2005-2009
    • Figure 89: CSL Limited, Return on Equity, (%), 2005-2009
    • Figure 90: DuPont Analysis for CSL Limited, 2005-2009
    • Figure 91: Therapeutic Focus of CSL Limited R&D Pipeline, 2009
    • Figure 92: R&D Productivity for CSL Limited, 2005-2009
    • Figure 93: Phase-wise Analysis of CSL Limited R&D Pipeline, 2009
    • Figure 94: SWOT Analysis of Celgene
    • Figure 95: Celgene, Annual Revenue Forecasts, ($m), 2004-2012
    • Figure 96: Celgene, Net Income and R&D Expense, ($m), 2004-2008
    • Figure 97: Celgene, Earnings per Share, ($), 2004-2008
    • Figure 98: Celgene, Net Profit Margin, (%), 2004-2008
    • Figure 99: Celgene, Current Ratio, 2004-2008
    • Figure 100: Celgene, Debt to Equity Ratio, 2004-2008
    • Figure 101: Celgene, Return on Equity, (%), 2004-2008
    • Figure 102: DuPont Analysis for Celgene, 2004-2008
    • Figure 103: Therapeutic Focus of Celgene R&D Pipeline, 2009
    • Figure 104: R&D Productivity for Celgene, 2004-2008
    • Figure 105: Phase-wise Analysis of Celgene R&D Pipeline, 2009
    • Figure 106: SWOT Analysis of Cephalon
    • Figure 107: Cephalon, Annual Revenue Forecasts, ($m), 2004-2012
    • Figure 108: Cephalon, Net Income and R&D Expense, ($m), 2004-2008
    • Figure 109: Cephalon, Earnings per Share, ($), 2004-2008
    • Figure 110: Cephalon, Net Profit Margin, (%), 2004-2008
    • Figure 111: Cephalon, Current Ratio, 2004-2008
    • Figure 112: Cephalon, Debt to Equity Ratio, 2004-2008
    • Figure 113: Cephalon, Return on Equity, (%), 2004-2008
    • Figure 114: DuPont Analysis for Cephalon, 2004-2008
    • Figure 115: Therapeutic Focus of Cephalon R&D Pipeline, 2009
    • Figure 116: R&D Productivity for Cephalon, 2004-2008
    • Figure 117: Phase-wise Analysis of Cephalon R&D Pipeline, 2009
    • Figure 118: SWOT Analysis of Actelion
    • Figure 119: Actelion, Annual Revenue Forecasts, ($m), 2004-2012
    • Figure 120: Actelion, Net Income and R&D Expense, ($m), 2004-2008
    • Figure 121: Actelion, Earnings per Share, ($), 2004-2008
    • Figure 122: Actelion, Net Profit Margin, (%), 2004-2008
    • Figure 123: Actelion, Current Ratio, 2004-2008
    • Figure 124: Actelion, Debt to Equity Ratio, 2004-2008
    • Figure 125: Actelion, Return on Equity, (%), 2004-2008
    • Figure 126: DuPont Analysis for Actelion, 2004-2008
    • Figure 127: Therapeutic Focus of Actelion R&D Pipeline, 2009
    • Figure 128: R&D Productivity for Actelion, 2004-2008
    • Figure 129: Phase-wise Analysis of Actelion R&D Pipeline, 2009
    • Figure 130: GBI Research Methodology